ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31
Zymeworks Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$25.54+0.51 (+2.04%)
Close on Oct 19, 2026
- Market cap
- $1.86B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$7.14 (+38.80%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Zymeworks Inc. saw revenue fall 69.8% to $37.13M over the twelve months to Jun 30, 2026. Free cash flow was -$120.54M.
Revenue
$37.13M
-69.8% vs. a year earlier
Operating income
-$155.56M
TTM Q2 2026
Free cash flow
-$120.54M
TTM Q2 2026
EPS, diluted
-$2.02
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.86B
- P/E ratio
- –
- Price to sales
- 50.21
- Price to book
- 23.20
- Dividend yield
- –
- Free cash flow yield
- -6.47%
Fundamentals
- Revenue
- $37.13M
- Net income
- -$149.99M
- EPS, diluted
- -$2.02
- Free cash flow
- -$120.54M
- Book value per share
- $1.10
- Diluted shares
- 73M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$37.13M-69.8% YoY
Operating income
-$155.56M
Net income
-$149.99M
EPS, diluted
-$2.02
Free cash flow
-$120.54M
Reported periodTrailing twelve months